Literature DB >> 7794063

An etiologic study of hemoglobinuria and blackwater fever in the Kivu Mountains, Zaire.

C Delacollette1, H Taelman, M Wery.   

Abstract

Between January 1985 and March 1986, in the high altitude area of Kivu, Eastern Zaïre, 38 patients presenting with hemoglobinuria as main manifestation were investigated. Profound glucose-6-phosphate dehydrogenase deficiency was detected in 4 patients, leptospirosis in 2 and Hantaan virus infection in 2. Hemolysis was doubtful (haptoglobin > 40 mg/dl, Hemoglobin > 12 g/dl) in 2 patients. Other potential causes of hemoglobinuria such as hemoglobinopathy, toxic agents, infectious diseases or blood transfusion incompatibility were carefully screened and excluded. The syndrome observed in the remaining 28 cases was strongly suggestive of blackwater fever (BWF) as described in malaria patients by several authors under the french name "fièvre bilieuse hémoglobinurique". Quinine was used as curative treatment of malaria before admission in a significant greater proportion (p < 0.01) of patients with BWF compared to patients with uncomplicated malaria, suggesting that this drug might have played a triggering role in the genesis of BWF. However, quinine was usually administered at inadequate doses to malaria patients non responding to chloroquine and belonging to a population of whom 50% are non immune. It may thus also be hypothesized that BWF in our patients could result from a hyperparasitemic state that remained undetected because of an unusual synchronous lysis of infected erythrocytes. In the latter case BWF would correspond to a major complication of falciparum malaria only coincidentally related to the use of quinine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794063

Source DB:  PubMed          Journal:  Ann Soc Belg Med Trop        ISSN: 0772-4128


  7 in total

1.  Blackwater fever: a fatal case.

Authors:  O Lesieur; P Dudeffant; B Courtiade; P Haglund
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

2.  Resurgence of blackwater fever among children in sub-Saharan Africa: a scoping review protocol.

Authors:  George Paasi; Carolyne Ndila; Florence Alaroker; Julian Abeso; Glorias Asiimwe; Francis Okello; Peter Olupot-Olupot
Journal:  BMJ Open       Date:  2022-07-06       Impact factor: 3.006

Review 3.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  High Frequency of Blackwater Fever Among Children Presenting to Hospital With Severe Febrile Illnesses in Eastern Uganda.

Authors:  Peter Olupot-Olupot; Charles Engoru; Sophie Uyoga; Rita Muhindo; Alex Macharia; Sarah Kiguli; Robert O Opoka; Samuel Akech; Carolyne Ndila; Richard Nyeko; George Mtove; Julius Nteziyaremye; Martin Chebet; Elizabeth C George; Abdel G Babiker; Diana M Gibb; Thomas N Williams; Kathryn Maitland
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

5.  Blackwater fever in Congolese children: a report of clinical, laboratory features and risk factors.

Authors:  Joseph M Bodi; Célestin N Nsibu; Roland L Longenge; Michel N Aloni; Pierre Z Akilimali; Pierre M Tshibassu; Patrick K Kayembe; Ahmeddin H Omar; Kenji Hirayama; Jan Verhaegen
Journal:  Malar J       Date:  2013-06-15       Impact factor: 2.979

Review 6.  Epidemiology of Leptospirosis in Africa: A Systematic Review of a Neglected Zoonosis and a Paradigm for 'One Health' in Africa.

Authors:  Kathryn J Allan; Holly M Biggs; Jo E B Halliday; Rudovick R Kazwala; Venance P Maro; Sarah Cleaveland; John A Crump
Journal:  PLoS Negl Trop Dis       Date:  2015-09-14

7.  Exploring association between MBL2 gene polymorphisms and the occurrence of clinical blackwater fever through a case-control study in Congolese children.

Authors:  Joseph M Bodi; Célestin N Nsibu; Roland L Longenge; Michel N Aloni; Pierre Z Akilimali; Patrick K Kayembe; Ahmeddin H Omar; Jan Verhaegen; Pierre M Tshibassu; Prosper T Lukusa; Aimé Lumaka; Kenji Hirayama
Journal:  Malar J       Date:  2020-01-15       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.